Recruiting

Observational Study

Sponsor:

World Federation of Hemophilia

Code:

NCT03327779

Conditions

Hemophilia A

Hemophilia B

Von Willebrand Diseases

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The WBDR is an international observational disease registry of patients with hemophilia. It will provide a platform for a network of hemophilia treatment centres (HTCs) around the world to collect uniform and standardized patient data and guide clinical practice. With informed consent from the patient, the WBDR stores anonymous data about the person's disease, such as hemophilia type and severity, symptoms, and treatment.

Conditions

Hemophilia A

Hemophilia B

Von Willebrand Diseases

Study ID

NCT03327779

Start date

Jan 26, 2018

Status verified date

Aug, 2023

Completion date

Jan, 2028

Anticipated

Primary completion date

Jan, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients of participating Hemophilia Treatment Centres with Hemophilia A or B, or von Willebrand Disease

Exclusion Criteria:

  • none

Study Design

Enrollment

20000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Number of participants recruited [ Time Frame: 5 years ]
  • Number of participating Hemophilia Treatment Centres [ Time Frame: 5 years ]
  • Number of participating countries [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Donna Coffin, M.Sc.

+15148757944dcoffin@wfh.org

Emily Ayoub, Ph.D.

+15148757944eayoub@wfh.org

Locations

World Federation of Hemophilia

Recruiting

Montréal, Quebec, Canada, H3G 1T7

Contacts

Donna Coffin, M.Sc.

+15148757944dcoffin@wfh.org

Emily Ayoub, Ph.D.

+15148757944eayoub@wfh.org

More Information

Sponsor

World Federation of Hemophilia

Last update posted

Aug 14, 2023

Last verified

Aug, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by World Federation of Hemophilia on 2023-08-14.